MRK Operating cash flow
Operating cash flow at Merck & Co. fell to $16.5B in fiscal 2025, from $21.5B in 2024.
Net cash provided by operating activities, as filed.
SOURCE: us-gaap:NetCashProvidedByUsedInOperatingActivities · EDGAR CompanyFacts · CIK 310158 · EDGAR ↗ · FY2020–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Operating cash flow | Change |
|---|---|---|
| FY2025 | $16.5B | $-5.0B |
| FY2024 | $21.5B | +$8.5B |
| FY2023 | $13.0B | $-6.1B |
| FY2022 | $19.1B | +$8.8B |
| FY2020 | $10.3B | — |
Cross-checks touching this measure FROM THE FILING REVIEW
◐ WATCHCash conversion stability
The ratio of operating cash flow to net income swings 33.60× across three years. Net income sits near zero in at least one year, so the ratio is an arithmetic artefact of a small denominator more than a cash story.
FY2025 10-K · FULL RECONCILIATION →◐ WATCHCapital returned vs free cash flow
Capital returned exceeded free cash flow (1.07×). Carried as watch; the red condition is 1.2× in two of three years.
FY2025 10-K · FULL RECONCILIATION →✓ CLEANStock compensation in cash flow
Share-based compensation is 5.0% of operating cash flow (threshold 15%).
FY2025 10-K · FULL RECONCILIATION →More SAME DATA, OTHER VIEWS
Operating cash flow across coverage → · MRK company view →
Revenue · Net income · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.